On October 21, Heyu Pharmaceutical announced that the company's self-developed selective oral small molecule FGFR2/3 inhibitor lavengratinib for the treatment of achondroplasia has been qualified as an orphan drug by the European Medicines Agency.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.